{"analyses":[{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.33","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7153","pValueComment":"Two-sided P-value","paramType":"Hazard Ratio (HR)","paramValue":"1.05","statisticalComment":"Strata: mutation status (KIT exon 9 vs. 11 vs. KIT/PDGFRA WT vs. other KIT {absence of exon 9 or 11}/PDGFRA) and intolerance to imatinib treatment","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.5","upperLimit":"10.8","value":"8.0"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"11.0","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"227"}],"units":"Participants"}],"description":"PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) Gastrointestinal stromal tumor (GIST) specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles","id":"OG000","title":"Ripretinib"},{"description":"Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"All patient (AP) Intent to Treat (ITT) Population is defined as all patients who are randomized. Patients in this population will be analyzed according to the treatment they were scheduled to receive.","reportingStatus":"POSTED","timeFrame":"From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)","title":"Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population","type":"PRIMARY","unitOfMeasure":"months"}